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ABSTRACT: Glucosamine and long-chain omego-3 lipid are the two most widely consumed marine nutraceuticals. These 
ingredients have been used as dietary supplement ingredients for many years, but are now becoming important functional 
food and beverage ingredients, The production of GRAS and vegetarian glucosamine has led to increased use of this 
ingredient in beverages in particular. For long-chain omega-3 lipid the development of stabilisation technologies has been 
critical for the increased use of these lipids in functional foods. The development of new sources of both of these 
ingredients, together with novel delivery and application technologies, will continue to drive increased consumption of 
these marine nutraceuticals, in particular as functional food and beverage ingredients. 
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INTRODUCTION 
Glucosamine is primarily consumed as a dietary supplement 
for the prevention or treatment of osteoarthritis, which 
affects about 21 million Americans and is the most common 
form of arthritis worldwide. Although the clinical evidence to 
support the efficacy of glucosamine is not conclusive, it is 
very strong. The two largest clinical trials on glucosamine for 
osteoarthritis were published recently, The NIH-sponsored 
multicenter study, known as the glucosamine/chondroitin 
arthritis intervention trial (GAIT), 
compared 1500 mg/day of 
glucosamine hydrochloride alone, 
1200 mg/day of chondroitin 
sulphate alone, glucosamine 
hydrochloride and chondroitin 
sulphate together, the drug 
Celecoxib (Celebrex), and a placebo for 24 weeks (1), The 
study found that for a subset of participants with moderate-
to-severe pain, glucosamine combined with chondroitin 
sulphate provided stotislically significant pain relief 
compared with placebo, with about 79 percent of 
participants having a 20 percent or greater reduction in pain 
versus about 54 percent for placebo. The second recent 
study, the glucosamine unum die efficacy (GUIDE) trial, was 
carried out on 300 participants in three groups, one taking 
1500 mg/day of glucosamine sulphate, 
the second 3000 mg/day of 
acetaminophen, and the third a 
placebo for 24 weeks (2). Results 
indicated that glucosamine sulphate 
was more effective than either placebo 
or acetaminophen at reducing pain. A 
recent systematic review and economic 
evaluation of the clinical effectiveness 
of glucosamine and chondroitin 
supplements concluded that there is 
evidence Ihat glucosamine sulphate 
shows some clinical effectiveness in the treatment of 
osteoarthritis (3). Strong clinical support and consumer 
awareness has enabled glucosamine to become an 
established dietary supplement ingredient with about a 10 
percent worldwide growth rate from 2003 to 2008. Sales in 
the USA alone were $872M in 2008 and about $2B globally. 
Glucosamine has hod less success as a rune tiona I food 
ingredient than as a dietary supplement ingredient, partly 
because the major source of glucosamine is from shrimp 
shells and is not Generally Recognised as Safe (GRAS) in the 
USA. Recent new sources of glucosamine with GRAS status, 
together with improved food and beverage formulation, 
have increased the use of glucosamine in food and 
beverages. A summary of new glucosamine sources and 
food and beverage formulations will be given below. 
The health benefits of the long-chain (LC) omega-3 fatty 
acids eicosapentaenoic acid (EPA) and docosahexaenoic 
acid (DHA) are established and 
have been the subject of 
numerous reviews (4-7). Although 
the clinical evidence is strongest 
for cardiovascular benefit LC 
omega-3s have a variety of 
health benefits and are 
considered wellness products, leading to relatively good 
success in functional foods. Approximately 300 new LC 
omega-3 fortified food products were introduced worldwide 
in 2006, 400 in 2007 and 700 in 2008, with global retail sales of 
these fortified foods expected to grow from about $5B in 
2008 to $8B in 2012 (8). Major brands such as Minute Maid, 
from Coca Cola, and Tropicana, from Pepsi, have launched 
LC omega-3 fOl'tified products. In addition to the functional 
food market, adding DHA to infant formulae has become 
the industry standard, with DHA fortified 
formulas representing about 70 percent 
of the total $9B global infant formula 
market. The dietary supplement market 
for I.C omega-3 also remains strong, 
with the majorily of ingredient in this 
segment being derived II'om fish. The 
major source of DHA in infanl formula is 
supplied by single cell organisms (SCO). 
mainly from the organism 
Crypthecodinium cohni; produced by 
Martek Biosciences, LC omega-3 for 
fortified food normally requires stabilisation through the use 
of microencapsulation and both SCQ and fish sources are 
being used in foods. New sources of LC omega-3 fatty acids, 
together with improved microencapsulation and delivery 
technologies, are helping 10 expand the use of this 
ingredient in foods. A summary of new sources and delivery 
technologies will be given below. 
PRODUCTION OF GRAS GLUCOSAMINE 
Recently vegetarian sources of glucosomine have been 
r1Avplnnpri Ip(viir.n In thp Irll ",rh nf Cn(nill'~ f;?c.flPnn<;, ,rp@ 
glucosamine derived from the fungus Aspergillus niger, 
Cyanotech's JOintAstin@produced through fermentation, 
and products from DNP Internationol ond Chino-based 
Hygieia Health. In 2007 Cargill obtained GRAS status for 
Regenosure@ making this product allowable for use in 
mainstream food and beverage applications. In addition to 
being GRAS Regenasure@ is vegetarian 
and kosher, overcoming key industry 
hurdles for use in foods in the USA. 
Glucosamine is derived from chitin, the 
second most abundant polymer on 
earth after cellulose. Chitin is primarily 
derived from shrimp and crab shells. 
However, chitin is also abundant in the 
cell walls of fungi such Aspergillus sp., 
Penicillium sp. and Mucor sp. 
Regenasure@ is derived from the 
common Aspergillus sp., Aspergillus niger (9). Glucosamine is 
produced from fungal biomass in a similar manner to how it 
is produced from shrimp shells. That is, the biomass is 
deproteinated using aqueous sodium hydroxide. Washed 
material is subsequently depolymerised using hydrochloric 
acid, and the glucosamine precipitated, washed and dried. 
Enzymes such as chitinases can be used for the 
depolymerisation step, but this method results in a more 
expensive process and so is not used industrially (10). 
GLUCOSAMINE FORMULATION IN FOODS 
Beverages containing glucosamine have been on the 
market in the USA for several years. One of the earliest 
giucosamine beverage products was Joint Juice ®, which 
contoins 1500 mg of Glucosamine hydrochloride per serving. 
Because of the non-GRAS status of shrimp shell derived 
glucosamine, products such as Joint Juice@were slarting to 
be targeted for review by the FDA. However, the 
introduction of Cargill's GRAS ingredient enabled beverage 
makers to replace their non-GRAS ingredient and overcome 
a key regulatory hurdle to having their products accepled in 
the mass market. The GRAS status of Regenasure@ has also 
enabled 1000ge multi-national companies with strong brands 
such as Coca-Cola to add glucosomine to their beverages. 
In 2007 Coco-Colo North America launched Minute Maid 
Active, which contains 750 mg of Glucosamine 
hydrochloride (Regenasure@) per serving os port 
of the Minute Moid 
Enhance Juice line. In 2000 
Pepsi purchased SoBe 
which sold functional 
beverages, including a 
glucosamine containing 
beverage for joint health. 
However, Pepsi has not yet 
launched a glucosomine 
product under it major 
brands such os Gatorade or 
Tropicana. 
Glucosamine is readily 
formulated into beverages 
since it is a highly water 
soluble, colourless 
ingredient. with little toste. 
Numerous beverages 
containing glucosamine 
flexmend 
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have been launched in the lost few years, some of which 
are shown in r:igure I. Glucosmnine has also been 
formulated into several food products, including cereal and 
vnnllrt Hn'Nr.>VP( nillrn~nnl;np. hpllArnnA<; hn\lC:> hppn '''llrh 
more successful than glucosamine foods. The total dollar 
volume of glucosamine containing foods and beverages is 
unclear. However, it is clear that by far the major 
component of the $2B glucosamine market is dietary 
supplements and functional foods and beverages sales are 
still small. Although there is high consumer awmeness of 
glucosamine, it is not considered a 
general wellness ingredient, which 
could inhibit its growth in mass market 
food and beverage applications. It will 
be interesting to walch the growth of 
this category over the next several 
years, especially with some suppliers 
getting European approval for their 
vegetarian glucosamine ingredients, 
including China-based Hygieia Health 
with GlucosaGreen®, although not yet 
for food use. Foods and beverages are targeted at a 
healthy population and can be consumed by a variety of 
people at various dosages. Cargill has applied for novel 
food ingredient status in Europe for Regenasure@, but this 
was delayed by the UK's Food Standards Agency due to a 
lack of information on whether it would affect people with 
diabetes. In late 2009 tile European Food Safety Authority 
has denied further health claims for glucosamine since 
claims need to show a reduction of disease risk and there is 
lack of clinical data on the ability of glucosamine to prevent 
cartilage degeneration outside of patients with osteoarthritis. 
Such regulatory decisions will make it difficult for 
glucosamine food and beverages to launch successfully in 
the EU. 
NEW SOURCES OF LONG-CHAIN OMEGA-3 FATTY ACIDS 
LC omega-3 fatty acids from fish oil are widely used in 
functional foods. New alternative sources of LC omega-3 will 
lead to expansion of the use of these fatty acids. These 
sources are primmily novel SCOs and genetically-modified 
plants. For example, Du Pont has developed both EPA and 
DHA producing yeast strains through metabolically 
engineering Yarrowia /ipo/ytica. Desaturase and elongose 
genes were introduced into the oleaginous yeast to 
synthesize these fatty acids under fermentation conditions. 
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These genetically modified yeasts con produce up to 55 
percent I.e 011l0go-3 in the accumulated oil under 
optimized conditions (11). Numel'ous other groups are 
t(l(lAtin(1 th(-: riAv(')inolYlAnt of notu(nl <ln0 0f:nlAtic:nliv 
modified seos for the production of Le omego-3 fatty acids. 
A number of groups are also targeting the development of 
plont sources. The most advanced is Monsanto, who have 
developed a genetically modified soybean oil rich in 
OI"nego-3, and have recently had a positive response fl'om 
the FDA with regard to their GRAS 
notice no. GRN 000283, essentially 
ruling that this modified oil is safe to 
eat. However. the Monsanto 
soybean product contains 
slearidonic acid rather than EPA or 
DHA, and so relies on the conversion 
in the body to especially EPA. 
Conversion from slearidonic acid to 
EPA is more efficient than from 
a~linolenic acid, the most common 
plant omega~3, but is still very 
inefficiently converted to DHA. 
Other companies, such as the world's largest chemical 
company BASF, are attempting to genetically modify plants 
to produce EPA and DHA. BASF is taking genes from marine 
algae and inserting them into canola and flax with the aim 
of producing canola or flax oils containing EPA and DHA. 
DuPont is working on producing genetically modified soya 
beans that are capable of converting ALA into EPA and 
DHA, using genes from the fungus Saprolegnia diC/ina, and 
have achieved up to 40 percent weight of the oil as LC 
omega~3 (12). The two key issues for commercialisation of 
these sources of LC omega-3 are consumer acceptance of 
genetically modified oils and price competitiveness with 
relatively low cost fish oils. 
NEW MICROENCAPSULATION STRATEGIES FOR DELIVERY OF LC 
OMEGA-3 TO FOODS AND BEVERAGES 
For many food applications microencapsulation is a 
necessary strategy for stabilising the sensory properties of LC 
omega-3 lipids, whether these lipids are derived from fish, 
microbial or genetically modified plant sources. Oils rich in 
EPA and DHA rapidly oxidise to form aldehydes with 
unpleasant taste and odour. which can make food 
unpalatable. For example, the LC omega-3 oxidative 
degradation product c-4-heptanal has a burnt fishy flavour 
at levels as low as 0.04 ppm, while t,c-3.6-nonadienal has a 
fish-like flavour and !'c-2,6-nonadienal has a green, fresh fish-
like flavour at levels as low as 0.0 I ppm. The most common 
method of stabilization these oils is through the use of 
microencapsulation to protect the oil from exposure to light 
and oxygen. effectively inhibiting the initiation of free-radical 
based oxidation of EPA and DHA. Several 
microencapsulation technologies are available and have 
been applied to fish oil to varying degrees of success. These 
include spray-dried emulsions, gravity-flow dry blending, 
fluidized bed cooling, molecular inclusion. iiposol1le 
entr'apment and single- and multi-core complex 
coacervalion (13). The most commercially developed 
processes are spray-dried emulsions and complex 
coacervation. Producing a spray-dried emulsion involves 
making an oil-in-water emulsion in the presence of protein or 
carbohydrate and spray drying the emulsion. Some 
limitations of spray-dried emulsions are that the particle size is 
normally large. Ihe oil payload is low at mound 30 percent, 
and the level of surface oil can be high. Clover Corporation 
of Australia has successfully applied a spray dried emulsion 
ingredient, which is stabilised using Maillard chemistry to 
cross-link protein and corbohydrate, to a variety of food 
products. This technology was developed by Food Science 
AII<;trolin nnrl rSIRn (14\. Mmtr"k hn<; Ink..,,, nrivnntnne ()f 
the versatility of shell material capable of forming spray dried 
emulsions to offer both protein and carbohydrate based 
encapsulated DHA, thereby satisfying Kosher, Halal, 
vegetarian and non-allergenic requil·ements. 
A novel variation of complex coacervation was developed 
by Ocean Nutrition Canada using a 
controlled aggregation process to 
form on agglomeration, followed by 
the controlled formation of on ouler 
shell surrounding the agglomeration, 
to produce a multi-shell particle (15, 
16). This method of "multicore" 
complex coacervation results in a 
high oil content of 60-70 percent by 
powder weight, leading to lower 
cost and less powder per serving to 
obtain a specific dosage. Multicore 
complex coacervation also leads to 
very low surface oil, probably because a shell is formed 
around the coacervate after agglomeration has occurred, 
improving sensory performance. However, a disadvantage 
of complex coacervation is that the shell material is currently 
limited to gelatin. Both a positively charged polymer and a 
negatively charged polymer are required for complex 
coacervation and certain gelation and gel setting properties 
are necessary for successful shell formation. Recent work at 
Ocean Nutrition Canada has led to the development of a 
whey protein based complex coacervate product. although 
this is still in development (17). Figure 2 compares the 
physical structure of the whey protein and gelatin powders. 
Figure 2. Comparison of Gelatine (lef!) and Whey prolein (right) lC omego-3 
powder produced using complex coocervolion (lhonks to Oceon Nutrilion 
Canada forimages). 
CONCLUSION 
Glucosamine and LC omega-3 lipids are by for the most 
widely used marine-derived nutraceuticals. Glucosamine is an 
established supplement ingredient but is only just starling to 
be used in food products. Glucosamine is having some 
success in beverage applications. particularly in the USA 
where GRAS status has been obtained for a vegetarian 
version. Further expansion of glucosamine as a functional 
food ingredient will depend upon an ability 10 get novel food 
status in a variety of countries. Also, glucosamine is not a 
general wellness ingredient. but rather a product targeted at 
osteoarthritis. This wilt inhibit its growth in foods, portly due to 
an inability to get health claims due to a lack of data outside 
of patients with osteoarthritis, and partly due to the difficulty in 
marketing a disease specific ingredient into foods. 
Glucosamine wlll likely have some success in targeted areas 
such as sports beverages, but Ihe jury is out os to whether this 
ingredient can effeclively penetrate into moss market food 
and bevemges despite the development of vegetarian 
sources and the ease or formulating with glucosomine. 
Omega-3 fatty acids have had more success than 
oli;r:o<;ominA in f()()(l<; nodlv rllJA to r:on,IJmer oewention of 
these ingredients as general wellness products. Alternotive 
sources other thon fish oil ore moving into the market, but the 
two major hurdles ore the generally high price of these 
sources and their being derived from genetically modified 
sources. In terms of delivery technologies, these are improving 
all the time, and the range of foods available that are fortified 
with omega-3 oils rich in EPA and DHA is increasing partly due 
to improved stabilisation technologies. There is still 
considerable room for market expansion of LC omega-3 
fottified foods and the next few years will determine how 
successful this ingredient will be in foods. 
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